Integrin-ligand interactions are regulated in a complex manner by divalent cations, and previous studies have identified ligand-competent, stimulatory, and inhibitory cation-binding sites. In collagen-binding integrins, such as ␣2␤1, ligand recognition takes place exclusively at the ␣ subunit I domain. However, activation of the ␣I domain depends on its interaction with a structurally similar domain in the ␤ subunit known as the I-like or ␤I domain. The top face of the ␤I domain contains three cation-binding sites: the metal-ion dependent adhesion site (MIDAS), the ADMIDAS (adjacent to MIDAS), and LIMBS (ligand-associated metal-binding site). The role of these sites in controlling ligand binding to the ␣I domain has yet to be elucidated. Mutation of the MIDAS or LIMBS completely blocked collagen binding to ␣2␤1; in contrast mutation of the ADMI-DAS reduced ligand recognition but this effect could be overcome by the activating monoclonal antibody TS2/16. Hence, the MIDAS and LIMBS appear to be essential for the interaction between ␣I and ␤I, whereas occupancy of the ADMIDAS has an allosteric effect on the conformation of ␤I. An activating mutation in the ␣2 I domain partially restored ligand binding to the MIDAS and LIMBS mutants. Analysis of the effects of Ca 2؉ , Mg 2؉ , and Mn 2؉ on ligand binding to these mutants showed that the MIDAS is a ligand-competent site through which Mn 2؉ stimulates ligand binding, whereas the LIMBS is a stimulatory Ca 2؉ -binding site, occupancy of which increases the affinity of Mg 2؉ for the MIDAS.
Integrins are a large family of receptors for extracellular and cell surface proteins (1, 2) . Integrin-ligand binding is regulated by divalent ions and conformational changes (3, 4) . The overall shape of an integrin is that of a large ligand-binding "head" on two long "legs" with flexible "knees." Integrins can exist in low affinity ("inactive") and high affinity (primed or "active") states; the balance between these states is regulated by both local and global conformational changes. The inactive form of the receptor has been shown to be bent with a closed headpiece, whereas the fully active form appears to be extended with an open headpiece (5, 6) . Integrins are heterodimers containing non-covalently associated ␣ and ␤ subunits. Eighteen ␣ subunits (␣1-␣11, ␣V, ␣IIb, ␣D, ␣E, ␣M, ␣L, and ␣X) and eight ␤ subunits (␤1-␤8) have been identified in mammals. Two subfamilies can be identified depending on the presence or absence of an autonomous folding domain of ϳ200 amino acids, the inserted or "I" domain in the ␣ subunit ("␣I"). 2 The I domain comprises a central hydrophobic six-stranded ␤-sheet surrounded by seven ␣-helices, with the characteristic divalent cation-binding sequence motif DXSXS forming part of the metal-ion dependent adhesion site (MIDAS) on the top face of the domain (7) . In each of the nine ␣I-containing integrins (␣1, ␣2, ␣10, ␣11, ␣E, ␣D, ␣M, ␣L, and ␣X), the MIDAS is the key site for ligand binding (8 -10) . I domains can exist in closed (inactive) or open (active) conformations, dependent upon a downward movement of the C-terminal ␣7 helix and an inward motion of the ␣1 helix (10, 11) . A domain sharing the same overall fold as the ␣I domain is present in all ␤ subunits (the I-like or "␤I" domain); this domain forms a major part of the ligand binding pocket in integrins that lack ␣I (12) (13) (14) .
Crystallographic studies of liganded, non-␣I domain containing ␣V␤3 and ␣IIb␤3 integrin segments (13, 14) have revealed the basis for the absolute dependence on divalent cations for ligand binding: a ligand carboxyl group coordinates to the cation present at the MIDAS of ␤I. The liganded ␤3 crystal structures also revealed two additional cation-binding sites in ␤I, the "ADMIDAS" site (adjacent to the MIDAS) and the "LIMBS" (ligand-associated metal-binding site). The ␤I MIDAS cation shares coordination residues with both the ADMIDAS and LIMBS, hence the three sites form a metal ion cluster (15) . The crystal structures of ␣IIb␤3 (14) also showed that the ␤I domain undergoes conformational shifts in its ␣1 and ␣7 helices that result in an outward swing of the underlying * This work was supported by grants from the Wellcome Trust (to M. J. H.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 To whom correspondence should be addressed: Michael Smith Bldg., Oxford Road, Manchester M13 9PT, United Kingdom. Tel.: 144-161-275-1558; Fax: 44-161-275-5082; E-mail: paul.mould@manchester.ac.uk. 2 The abbreviations used are: ␣I, ␣ subunit I-domain (also known as ␣A); ␤I, ␤ subunit I-domain (also known as ␤A); MIDAS, metal-ion dependent adhesion site; ADMIDAS, adjacent to MIDAS; LIMBS, ligand-associated metalbinding site; mAb, monoclonal antibody; FL␣2, ␣2-(1-1129)-Fc construct; TR␣2, ␣2-(1-806)-Fc construct; FL␤1, ␤1-(1-708)-Fc construct; TR␤1, ␤1-(1-455)-Fc construct; FL␣2␤1-Fc, recombinant soluble integrin heterodimer containing the complete extracellular domains of ␣2 and ␤1 subunits fused to the C H 2 and C H 3 domains (Fc region) of human IgG␥1; TR␣2␤1-Fc, recombinant soluble integrin heterodimer containing C-terminal-truncated ␣2 and ␤1 subunits fused to the C H 2 and C H 3 domains of human IgG␥1; CHO, Chinese hamster ovary.
hybrid domain in the open (active) conformation of the ligandbinding integrin headpiece.
Although ligand binding in integrins that contain the ␣I domain does not directly involve ␤I, the C-terminal connecting loop between ␣I and the ␤-propeller contains a critical glutamate residue, which is proposed to bind to the ␤I MIDAS (16, 17) . Binding of this loop is proposed to pull downwards on the ␣7 helix of ␣I, holding it in an open (active) conformation (18 (21) . In contrast, the ADMIDAS was found to be a Ca 2ϩ -binding inhibitory site in ␣5␤1 (22) . Although the LIMBS is a candidate for a Ca 2ϩ -binding stimulatory site, it was not possible to test this suggestion for ␣5␤1 because mutation of this site led to a complete loss of ligand recognition (22) . Mutation of this site in ␤2 and ␤3 integrins also abrogates ligand binding (23) (24) (25) (26) (27) (28) . Hence, the identity of the stimulatory site is not fully resolved.
Previous studies on ␣4␤7 have delineated separate functions for each of three ␤I cation-binding sites in this integrin (15, 29) . However, it is unclear if these findings are broadly applicable, e.g. to ␤1 integrins or to integrins that contain an ␣I domain. To study the regulation of ligand binding by divalent ions in an ␣I-containing integrin, we expressed the collagen receptor ␣2␤1 in a recombinant soluble form. To elucidate the roles of the MIDAS, ADMIDAS, and LIMBS we mutated critical residues for cation binding in the ␤I domain and tested for ligand binding ability and regulation by divalent cations in solid phase assays. In this system, an activating mutation in the ␣2 I domain was found to partially overcome the effect of LIMBS mutations, thereby allowing us to test whether the LIMBS is a stimulatory site. Our results demonstrate that the three sites have distinct roles in the regulation of collagen binding to the ␣2 I domain, and that the LIMBS is essential for the stimulation of Mg 2ϩ -supported ligand binding by Ca 2ϩ .
EXPERIMENTAL PROCEDURES
Monoclonal Antibodies-Mouse anti-human ␤1 mAbs 12G10 and 8E3 were produced as described (30, 31) . Mouse anti-human ␤1 mAb TS2/16 was a gift from Dr. F. Sánchez-Madrid (Hospital de la Princesa, Madrid, Spain). Mouse antihuman ␤1 mAb 15/7 was a gift from Dr. T. Yednock (Elan Pharmaceuticals, South San Francisco, CA). Mouse anti-human ␤1 mAbs 4B4 and HUTS-4 were purchased from Beckman Coulter (High Wycombe, UK) and Chemicon (Harrow, UK), respectively. Mouse anti-human ␣2 mAbs JA218 and JA212 were produced as previously described (32) . Mouse anti-human ␣2 mAbs Gi9, P1E6, and 12F1 were from Beckman Coulter, Chemicon, and BD Biosciences (Oxford, UK), respectively. All mAbs were used as purified IgG.
Proteins-Integrin ␣2␤1 was purified from HT-1080 cells as previously described (32) . Type I collagen (from rat-tail tendon) was obtained from Sigma. Collagen was biotinylated as described before (32) using sulfo-LC-NHS biotin (Perbio, Chester, UK). The ␣2 I domain-glutathione S-transferase fusion protein was produced in Escherichia coli as described (33) .
Expression Vector Construction and Mutagenesis-Human ␣2 cDNA was obtained from D. Tuckwell (University of Manchester). C-terminal-truncated human ␣2 constructs encoding residues 1-806 (TR␣2) or 1-1129 (FL␣2), and C-terminal-truncated human ␤1 constructs encoding residues 1-455 (TR␤1) or 1-708 (FL␤1) were generated essentially as previously described (34) . Both ␣ and ␤ constructs were fused in-frame to the hinge regions and C H 2 and C H 3 domains of human IgG␥1 (i.e. the Fc portion of the heavy chain). The sequence of the constructs was verified by DNA sequencing. To aid the formation of heterodimers, the C H 3 domain of the ␣2 construct contained a "hole" mutation, whereas the C H 3 domain of the ␤1 constructs carried a "knob" mutation as described (35) . Mutagenesis of ␤I domain cation-binding sites was carried out as described before (6, 22) . Oligonucleotides were purchased from MWG Biotech (Southampton, UK). All constructs were verified by DNA sequencing.
Transfection of ␣2-and ␤1-Fc Constructs-Chinese hamster ovary cells L761h variant (34) were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 2 mM glutamine, and 1% non-essential amino acids (growth medium). 75-cm 2 flasks of subconfluent CHO-L761h cells were transfected with 5 g of ␤1 construct, and 5 g of ␣2 construct using LipofectaminePLUS reagent or Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. After 4 days, culture supernatants were harvested by centrifugation at 300 ϫ g for 5 min.
Reactivity of Anti-␣2 and Anti-␤1 mAbs with Recombinant Receptors-96-Well plates (Costar 1 ⁄ 2-area EIA/RIA, Corning Science Products, High Wycombe, UK) were coated with goat anti-human Fc (Jackson ImmunoResearch) at a concentration of 2.6 g/ml in Dulbecco's phosphate-buffered saline (50 l/well) for 16 h. Wells were then blocked for 1 h with 200 l of 5% (w/v) bovine serum albumin, 150 mM NaCl, 0.05% (w/v) NaN 3 , 25 mM Tris-Cl, pH 7.4 (blocking buffer). The blocking solution was removed and the wells were then washed three times with 200 l of 150 mM NaCl, 25 mM Tris-Cl, 1 mM MnCl 2 , pH 7.4, containing 1 mg/ml bovine serum albumin (buffer A). Cell culture supernatants (50 l/well) were added and the plate incubated at room temperature for 1 h. Wells were washed three times in buffer A and anti-␣2 or anti-␤1 mAbs (10 g/ml in buffer A) were then added (50 l/well). The plate was incubated for 2 h at room temperature and then washed 3 times in buffer A. Peroxidase-conjugated anti-mouse or anti-rat Fc secondary antibody (1:1000 dilution in buffer A; Jackson ImmunoResearch) was added (50 l/well) for 30 min, the plate was washed four times in buffer A, and color was developed using the 2,2Ј-azinobis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) substrate. Background binding of mAbs to wells incubated with supernatant from mock-transfected cells was subtracted from all measurements. Measurements obtained were the mean Ϯ S.D. of three replicate wells.
Collagen Binding Assays-96-Well plates were coated with goat anti-human Fc at a concentration of 2.6 g/ml in Dulbecco's phosphate-buffered saline (50 l/well) for 16 h. Wells were then blocked for 1-3 h with blocking buffer, and then washed three times with buffer A. Cell culture supernatants (50 l/well) were added and the plate incubated at room temperature for 1 h. Wells were washed three times in buffer A and biotinylated collagen type I (0.03-10 g/ml) in buffer A was added to the plate (50 l/well), either alone, or in the presence of mAb TS2/16 (5 g/ml). The plate was then incubated at room temperature for 2 h. Unbound ligand was removed and the wells washed three times with buffer A. Bound ligand was quantitated by addition of 1:500 dilution of ExtrAvidin peroxidase conjugate (Sigma) in buffer A for 20 -30 min at room temperature (50 l/well). Wells were then washed four times with buffer B, and color was developed using ABTS substrate (50 l/well). Background binding of collagen to wells incubated with supernatant from mock-transfected cells was subtracted from all measurements. Measurements obtained were the mean Ϯ S.D. of three replicate wells. In all assays comparing the binding of collagen to wild-type and mutant receptors, the level of ligand binding to mutant receptors was normalized relative to that of wild-type by measuring the binding of the anti-␣2 mAb JA218 to a parallel set of three replicate wells for each receptor; this mAb only recognizes the heterodimeric state of the integrin; normalization factor ϭ (JA218 binding to wildtype receptor Ϫ background binding/(JA218 binding to mutant receptor Ϫ background binding).
Divalent Cation Regulation of Collagen Binding-96-Well plates were coated with goat anti-human Fc at a concentration of 2.6 g/ml in Dulbecco's phosphate-buffered saline (50 l/well) for 16 h. Wells were then blocked for 1-3 h with blocking buffer, and then washed three times with buffer B (150 mM NaCl, 25 mM Tris-Cl, pH 7.4, containing 1 mg/ml bovine serum albumin). Buffer B was treated with Chelex beads (Bio-Rad) to remove any small contaminating amounts of endogenous Ca 2ϩ and Mg 2ϩ ions. Cell culture supernatants (50 l/well) were added and the plate incubated at room temperature for 1 h. Wells were washed three times in buffer B and biotinylated collagen (0.5 g/ml) in buffer B was added to the plate (50 l/well) in the presence of varying concentrations of Mn 2ϩ , Mg 2ϩ , and Ca 2ϩ , or varying concentrations of Ca 2ϩ with Mg 2ϩ . The remainder of the assay was performed as described above.
Divalent Cation Regulation of Collagen Binding to ␣2 I Domain-96-Well plates were coated with recombinant ␣2 I-domain-glutathione S-transferase fusion protein at a concentration of 10 g/ml in Dulbecco's phosphate-buffered saline (50 l/well) for 16 h. Wells were then blocked for 1-3 h with blocking buffer, and then washed three times with buffer B. Biotinylated collagen (0.5 g/ml) in buffer B was added to the plate (50 l/well) in the presence of varying concentrations of Mn 2ϩ , Mg 2ϩ , and Ca 2ϩ , or varying concentrations of Ca 2ϩ with Mg 2ϩ . The remainder of the assay was performed as described above.
Calculation of Apparent K d Values-Binding of biotinylated collagen I to wild-type of mutant integrin was measured using solid phase assays as described above, over a range of collagen concentrations (0.1-10 g/ml). Apparent affinity (apparent K d ) of binding was estimated by non-linear regression analysis using SigmaPlot version 8 (Systat Software Inc.), assuming a single class of binding sites.
RESULTS

Expression of Recombinant Soluble ␣2␤1-Fc Integrins Produces Functional "Full-length" and Truncated
Receptors-Recombinant integrins were produced in a CHO cell expression system by cloning the extracellular portions of ␣2 and ␤1 integrin cDNAs and replacing the transmembrane and cytoplasmic domains with modified Fc tags to favor heterodimerization (34, 35) . The soluble ␣2␤1-Fc comprising the full-length extracellular domains of ␣2 and ␤1 is referred to as FL␣2␤1-Fc. In addition, ␣2 was modified by deleting 326 amino acids from its C-terminal end. The truncated subunit contains the headpiece region of ␣2, i.e. the ␤-propeller, ␣I domain, and the thigh domain. A parallel truncation in the ␤1 subunit (34) contains the PSI, ␤I, and hybrid domains. These two truncated subunits form a "minimized" heterodimer referred to here as TR␣2␤1-Fc.
To assess whether the soluble integrins retained the native fold, anti-human ␣2 and ␤1 integrin monoclonal antibodies were examined for their ability to bind to the recombinant proteins in enzyme-linked immunosorbent assays (Table 1) . Recombinant receptors were captured from CHO cell culture supernatants with anti-human Fc antibody onto microtiter plates and the binding of anti-integrin mAbs was evaluated. A panel of mAbs directed against ␣2 (12F1, JA218, Gi9, and P1E6) and ␤1 (4B4, 8E3, 12G10, and TS2/16) recognized the FL and the TR␣2␤1-Fc integrins to a similar extent as native ␣2␤1 purified from HT-1080 cells (Table 1 , panel A). The ␣2 mAbs directed against the ␣I domain (12F1, Gi9, and P1E6) did not recognize the ␣2 constructs when these were transfected in the absence of a ␤1 subunit (data not shown). Western blotting of supernatants confirmed that heterodimer formation had taken place (Fig. 1, A and B) . Following confirmation of the correct protein folding and assembly, the soluble integrins were tested for collagen binding activity in solid phase assays (Fig. 2) . The assays were performed in the presence either Mg 2ϩ ( Fig. 2A) or Mn 2ϩ (Fig. 2B) , using a concentration of the cation that supported maximal ligand binding. The FL and TR␣2␤1-Fc integrins bound collagen I to comparable extents in both Mg 2ϩ and Mn 2ϩ , and specific collagen binding was cation-dependent as it was completely blocked by EDTA. In the presence of TS2/16, a stimulatory mAb that binds to the ␤I domain, collagen binding was unchanged for FL␣2␤1 and only slightly increased for the TR␣2␤1-Fc integrin. Hence, both FL and TR␣2␤1-Fc appear to be almost completely in an active form.
Mutations in the ␤I Cation-binding Sites Inactivate TR␣2␤1-Fc-To study the role of the ␤1 I domain cation-binding sites in regulation of ␣2␤1 function, residues that form the sites (Table 2) were selected for mutagenesis in the TR␣2␤1-Fc expression system. Each mutant contained an amino acid substitution of a single residue forming one of the three cation- (Table  2) . Of these residues Glu 229 is also an integral residue of the MIDAS, and Pro 228 contributes only a backbone carbonyl. The side chain of Asn 224 is specific for the LIMBS but also participates in ligand binding (13) . Thus, Glu 169 and Asp 226 were targeted as these are specific for the LIMBS and substitution of either Glu 169 or Asp 226 to alanine would be expected to abrogate cation binding to the LIMBS only. In parallel, a conservative mutation Glu 169 to Asp, was examined as a control. This mutation is unlikely to perturb cation binding because an aspartate residue is present in place of glutamate at this position in almost all the other ␤ subunits. The effect of these mutations was examined in the context of the TR␣2␤1-Fc protein. Expression of each recombinant integrin and protein folding were monitored using conformation-sensitive anti-human ␣2 and ␤1 integrin mAbs (Table 1 , panel A). Because these antibodies recognized the wild-type and mutated receptors to similar extents, it was concluded that the mutations had no gross effect on the conformation. Western blotting confirmed that correct heterodimer formation had occurred (Fig. 1, A and B) .
Next, we assessed the collagen-binding activity of the Fccaptured ␣2␤1-Fc variants in solid phase assays (Fig. 3, A and  B) . Of the six mutant integrins, only the control LIMBS E169D mutant bound collagen I to the same extent as wild-type TR␣2␤1. In contrast, the LIMBS D226A and E169A mutants did not support collagen binding under any experimental condition, with or without the stimulatory TS2/16 antibody. The ␤1 MIDAS D130A mutation also abolished ligand binding, although weak binding was observed in the presence of TS2/16 and Mg 2ϩ . In contrast, ADMIDAS mutants D137A and D138A showed a moderate level of collagen binding, and addition of TS2/16 restored ligand binding to the same level as that for the wild-type integrin. Hence, the ADMIDAS mutants were partially active, whereas the LIMBS and MIDAS mutants were essentially inactive.
To investigate further the activation state of the ADMIDAS mutants, we examined the binding of the activating mAbs HUTS-4 and 15/7 to ␣2␤1D137A and ␣2␤1D138A (Table 1 , panel A). These mAbs recognize the swung-out conformation of the hybrid, and thereby report an open headpiece (6). The results showed that both ADMIDAS mutants had strongly decreased expression of the HUTS-4 and 15/7 epitopes, suggesting that these mutants mainly adopt the closed headpiece conformation. The expression of these epitopes on the ADMI-DAS mutants was partially restored in the presence of TS2/16 (data not shown). Although the MIDAS and LIMBS mutations resulted in non-functional integrins these mutations did not lead to a reduction of HUTS-4 and 15/7 binding (Table 1, panel  A) . Hence, these mutations did not affect the activation state of the integrin; instead, it appears that the LIMBS and MIDAS are required for the interaction of the ␤I domain with the ␣2 I domain.
The ␣2[I332G] Mutation Promotes the Active Conformation of ␣2␤1-Because the ␣2␤1-Fc LIMBS and MIDAS mutants were inactive for collagen binding, we investigated whether an activating mutation in the ␣I domain could restore ligand binding. Activation of ␣I-containing integrins by substitution of a conserved isoleucine residue in the ␣7 helix has been demonstrated by a number of studies (9, 16, 36) . To test whether a similar mutation in ␣2 could rescue the ability of the ␤I domain mutants to bind to collagen, an Ile 332 to Gly mutation (I332G) was introduced into the truncated ␣2 subunit. The TR␣2[I332G]-Fc subunit was co-expressed with the wild-type or cation-binding site-mutated ␤1-Fc subunits in CHO cells. The resulting seven mutants were examined for expression and correct folding in Fc-capture assays and Western blotting. The anti-␣2 and anti-␤1 mAbs recognized the TR␣2[I332G]␤1-Fc mutants to a similar extent as the wild-type TR␣2␤1-Fc (Table  1 , panel B), and each of the mutants formed a heterodimer (Fig.  1, C and D) . Thus, the ␣2[I332G]␤1-Fc and all six double mutants assembled correctly and acquired a native fold.
The ability of the mutants to bind collagen I was then examined in solid phase assays (Fig. 4, A and B) . The ␣2 activating mutation enhanced the low collagen binding levels of the D137A and D138A ADMIDAS mutants to levels close to those observed for the wild-type receptor in Mg . The activating mutation also restored 15/7 and HUTS-4 binding to these mutants to a level similar to that of wildtype integrin (Table 1, panel B) . In addition, the MIDAS (D130A) mutant and both LIMBS (D226A, E169A) mutants 
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2ϩ to Support Ligand Binding-Next, we examined the effect of the ␤1 cation-binding site mutations on the specificity and requirement for cations in collagen binding, and compared it to that for purified ␣2␤1 and for the solitary ␣2 I domain. As shown previously, the binding of purified ␣2␤1 to collagen type I was supported strongly by Mn 2ϩ and to a lesser extent by Mg 2ϩ , but not by Ca 2ϩ (Fig. 5A) . A similar profile of cation regulation was observed for both the FL and TR␣2␤1-Fc (Fig. 5,  B and C) . The Mn 2ϩ and Mg 2ϩ concentrations required to support half-maximal collagen binding were very close to those observed for the purified ␣2␤1. Thus, the results showed that ligand binding to the Fc-fusion proteins was modulated by divalent cations in a very similar manner to the purified integrin. The cation dependence of collagen binding to the solitary ␣2 I domain was also studied (Fig. 5D) . The results showed that Mg 2ϩ was slightly more effective than Mn 2ϩ at supporting collagen binding. Hence, the observed stimulation of ligand binding by Mn 2ϩ in the parental receptor derives from cation-binding sites outside of the ␣I domain.
Next, the effect of Mn 2ϩ , Mg 2ϩ , and Ca 2ϩ on collagen binding to the constitutively active mutant TR␣2[I332G]␤1-Fc and cation-binding site double mutants was examined over a range of divalent cation concentrations (Fig. 5, E-J) . For all the recombinant proteins, Mn 2ϩ and Mg 2ϩ but not Ca 2ϩ ions support the binding of collagen. As observed for the wild-type integrins Mn 2ϩ promoted higher maximal levels of collagen binding than Mg 2ϩ to the ADMIDAS and LIMBS mutants (Fig. 5,  G-J) . In contrast, for the MIDAS mutant (Fig. 5F) concentrations for the wild-type and mutant receptors. In agreement with previous reports (37, 38) low Ca 2ϩ concentrations increased the Mg 2ϩ -dependent collagen binding to the purified ␣2␤1 integrin, whereas Ca 2ϩ ions at concentrations above 0.25 mM had an inhibitory effect on ligand binding (Fig.  6A) . Similarly, Ca 2ϩ concentrations below 0.25 mM reproducibly increased Mg 2ϩ -dependent collagen binding to both FL and TR recombinant ␣2␤1-Fc integrins; however, increasing the Ca 2ϩ concentration above 0.25 mM decreased collagen binding and strong inhibition of collagen binding occurred at 2 mM Ca 2ϩ (Fig. 6, B and C) (Fig. 6D) (Fig. 6F) . Furthermore, it was also observed that Ca 2ϩ concentrations in the range of 0.25-2 mM did not inhibit significantly collagen binding. Thus, Ca 2ϩ ions were less effective in inhibiting collagen binding to the MIDAS mutant than to the ADMIDAS or LIMBS mutants.
DISCUSSION
In this study we have used a recombinant soluble ␣2␤1-Fc integrin system to study the contribution of each of the ␤I domain cation-binding sites to the regulation of ligand binding to the ␣I domain. Our major findings are the following. A cell-free system was chosen to study the role of cationbinding sites in ligand recognition by ␣2␤1 to avoid potential confounding effects due to the effects of divalent ions on cell signaling and interactions with other proteins. This is the first report of a functional ␣I domain-containing integrin preparation with a truncated extracellular domain. Our data show that the headpiece (␤-propeller, I domain, and thigh domain of ␣2, with PSI, hybrid, and I domain of ␤1) of ␣2␤1 is sufficient for native folding and ligand recognition. The TR␣2␤1-Fc recombinant proteins were also constitutively active for ligand binding; this is in contrast to the equivalent TR␣5␤1-Fc and TR␣4␤1-Fc proteins, which were found to be almost completely inactive (22, 34, 39) . In addition, we found that the ␣2 I domain does not fold autonomously in the context of the ␣2 ␤-propeller domain; instead, association with the ␤1 subunit is necessary. This finding contrasts with a previous report that folding of the ␣M I domain can occur independently of association with the ␤2 subunit (40) . ). In contrast, we observed that the ADMIDAS mutants were more dependent on the presence of Mn 2ϩ for ligand binding than the wild-type receptor, similar to the results obtained for ␣5␤1 (22) . Furthermore, we found that mutation of the AMIDAS did not alter the stimulatory effect of Mn 2ϩ in the constitutively active (I332G) mutant, whereas mutation of the MIDAS abrogated this effect. Hence, our data support the alternative paradigm that the ␤I MIDAS is the site through which Mn 2ϩ exerts its effects on ligand recognition (4). The differences between Mn 2ϩ and Mg 2ϩ in their abilities to stimulate ligand binding appears to be a conse- quence of the distinct capacities of these two ions to promote shape shifting in the ␤I domain (21) Evidence to support the positive Ca 2ϩ -regulatory role of LIMBS has also been presented for cell surface-expressed ␣4␤7 integrin (a non-␣I domain-containing integrin) (13) . The synergistic effects of low Ca 2ϩ and Mg 2ϩ concentrations were shown to require the LIMBS but not the ADMIDAS. In the same study, disruption of the LIMBS (by a mutation equivalent to the D226A mutation in ␤1) impaired the firm adhesion of cells on MAdCAM-1-coated surfaces, but did not block rolling. In contrast, mutation of the LIMBS in ␣2␤1 (this study) and ␣5␤1 abolishes ligand binding. Mutation in the LIMBS in ␤2 and ␤3 integrins has also been found to block ligand recognition (23) (24) (25) (26) (27) (28) 42) . Mutation of the ADMIDAS resulted in a constitutively active (although bent) integrin in ␣4␤7 (15, 29, 43) and ␣L␤2 (27) , whereas for ␣2␤1 (this study) and ␣5␤1 (22) mutation of the ADMIDAS resulted in a constitutively inactive receptor. Subtle differences in the coordination of the ␤I cation-binding sites among different integrins could account for these discrepancies.
Our results are in good agreement with data from the crystal structure of the ligand-occupied headpiece region of ␣IIb␤3 (14) . In this structure the MIDAS was occupied by Mg 2ϩ , whereas the ADMIDAS and LIMBS were occupied by Ca 2ϩ . The higher propensity of Ca 2ϩ than Mg 2ϩ or Mn 2ϩ to coordinate carbonyl oxygen atoms (44) may explain why Ca 2ϩ will preferentially bind to the ADMIDAS and LIMBS rather than to the MIDAS, which lacks any carbonyl oxygen coordination (13, 14) . The LIMBS could act as the stimulatory Ca 2ϩ site because occupancy of the LIMBS may reorient and stabilize the side chain carboxyl of Glu 220 (Glu 229 in ␤1), thereby favoring occupancy of the MIDAS, which is also coordinated by the same carboxyl group.
In summary, we have shown that the three ␤I cation-binding sites have distinct roles in ligand binding by ␣2␤1. Our findings are likely to be broadly applicable to ␤1 integrins and to integrins that contain ␣I. The interaction of platelet ␣2␤1 with collagen is a critical step during hemostasis and changes in the extracellular concentrations of Mg 2ϩ and Ca 2ϩ after wounding may regulate collagen binding in vivo (45) . Similarly, alterations in the extracellular fluxes of these ions may alter tumor cell proliferation and migration (46) . Our novel insights into the mechanisms of ␣2␤1 regulation should assist in the development of ␣2␤1 antagonists for therapeutic use (47, 48) . Dimitra Valdramidou, Martin J. Humphries and A. Paul Mould
